A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

I5B-MC-JGDP -

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Pancreatic Cancer
What the trial is testing?
Gemcitabine, Nab-paclitaxel, Olaratumab
Could I receive a Placebo?
Yes
Enrollment Goal
184
Trial Dates
Jun 22, 2017 - Jun 17, 2021
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have metastatic (stage 4) pancreatic cancer diagnosis

  • Participant must have tumor tissue available or be willing to provide a biopsy

  • Participant must have discontinued all previous treatments for cancer at least 4 weeks prior

  • Participant must have a life expectancy of at least 3 months

Participants Must Not:

  • Participant must not have had first line treatment for metastatic pancreatic cancer

  • Participant must not have participated in another clinical trial within the last 30 days

  • Female participant must not have a positive pregnancy test or be lactating

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.